Pasar al contenido principal

ANALISIS Y MEJORA DE LA ADECUACION DE LA PRESCRIPCION DE QUIMIOTERAPIA AL FINAL DE LA VIDA

PI18/00034

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer, A Mapping Review and Evidence Gap Map

  • Requeijo, Carolina|||0000-0003-3479-4550
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Meza, Nicolás|||0000-0001-9505-0358
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Salazar, Josefina|||0000-0002-6448-5946
  • Santero, Marilina|||0000-0001-5371-0979
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Rodríguez-Grijalva, Gerardo
  • Selva, Anna|||0000-0002-2754-3158
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Despite being commonly recommended, the impact of anticancer drugs (ACDs) on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) may not have been sufficiently assessed. We aim to identify and map the evidence regarding ACDs versus best supportive care (BSC) for advanced HBCs, considering patient-centered outcomes. In this mapping review, we included systematic reviews, randomized controlled trials, quasi-experimental, and observational studies comparing ACDs (chemotherapy, immunotherapy, biological/targeted therapy) versus BSC for advanced HBCs. We searched MEDLINE (PubMed), EMBASE (Ovid), Cochrane Library, Epistemonikos, PROSPERO and clinicaltrials.gov for eligible studies. Two reviewers performed the screening and data extraction processes. We developed evidence maps for each type of cancer. We included 87 studies (60 for advanced liver cancer and 27 for gallbladder or bile duct cancers). Most of the evidence favored ACDs for survival outcomes, and BSC for toxicity. We identified several evidence gaps for non-survival outcomes, including quality of life or quality of end-of-life care. Patient-important outcomes beyond survival in advanced HBCs are insufficiently assessed by the available evidence. Future studies need to address these gaps to better inform decision-making processes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research, an analysis of anticancer drugs versus supportive care in advanced esophageal cancer

  • Santero, Marilina|||0000-0001-5371-0979
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Selva, Anna|||0000-0002-2754-3158
  • Savall-Esteve, Olga|||0009-0002-2685-1797
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Macias Declara, Ismael
  • Leache, Leire|||0000-0003-2272-7086
  • Cerdà, Paula|||0000-0003-0101-188X
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Antequera, Alba|||0000-0002-1670-6302
  • Auladell-Rispau, Ariadna|||0000-0002-0364-4827
  • Cantero-Fortiz, Yahveth|||0000-0003-0329-6487
  • Hernández, Edgar D.
  • Irassar, Juan
  • Meinardi, Pamela
  • Merchán Galvis, Ángela María|||0000-0003-2375-5513
  • Meza, Nicolás|||0000-0001-9505-0358
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Rodríguez-Grijalva, Gerardo
  • Salas-Gama, Karla|||0000-0003-4845-4899
  • Salazar, Josefina|||0000-0002-6448-5946
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
Background: Highlighting the identified gaps in evidence-based research concerning advanced esophageal cancer (EC) treatment and care, this review evaluates the efficacy and safety of anticancer drugs compared to supportive care for advanced EC patients, aiming to assess the appropriateness of usual treatments and identify the gaps that need to be filled with primary research. Methods: We searched (May 2022) MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Epistemonikos, and trial registries (ClinicalTrials.gov and PROSPERO) for randomised controlled trials (RCTs) comparing anticancer drugs (chemotherapy, immunotherapy, or biological/targeted therapy) with supportive care in advanced EC. The results were summarised using GRADE summary of finding tables. Results: We included 15 RCTs. Most studies did not have a special focus on EC, did not detail the treatment lines in all patients, and did not evaluate all outcomes. Anticancer drugs may result in a slight increase in overall survival (OS) (HR 0.78; 95% CI 0.71, 0.86; MD 0.83 months) and better progression-free survival (PFS) (HR 0.56 95% CI 0.49, 0.64, MD 0.68 months), but also may increase toxicity (RR 1.37; 95% CI 1.13, 1.65), without a significant improvement in quality of life. The certainty of evidence was low or very low due to indirectness of results and lack of specific focus on EC in some studies. Conclusion: RCTs on advanced EC lack specificity, detailed treatment line information, and evaluation of all relevant outcomes. Moreover, when they find any benefit, this is negligible. Therefore, the certainty to justify anticancer drug treatments instead of supportive care in advanced EC is low or very low, and this information should be actively shared with affected patients. More and better RCTs should be conducted to assess whether any old or new proposed treatment for advanced EC patients provides a better balance of benefits and harms than the supportive care. Systematic review registration: The study protocol was registered in OSF (https://doi.org/10.17605/OSF.IO/7CHX6) on 2022-03-29.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer, A Systematic Review and Meta-analysis of Randomized Trials

  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Santero, Marilina|||0000-0001-5371-0979
  • Savall-Esteve, Olga|||0009-0002-2685-1797
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Leache, Leire|||0000-0003-2272-7086
  • Selva, Anna|||0000-0002-2754-3158
  • Macias Declara, Ismael
  • Cerdà, Paula|||0000-0003-0101-188X
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Purpose: To assess the efficacy and safety of non-chemotherapy anticancer drugs (immunotherapy or targeted therapy) compared to best supportive care (BSC) or placebo for the treatment of advanced gastric cancer (GC). Methods: Systematic review of randomized controlled trials (RCTs) searching (May 2022) MEDLINE, EMBASE, CENTRAL, Epistemonikos, ClinicalTrials.gov, and PROSPERO. Certainty of evidence was evaluated following GRADE. Results: Six RCTs included. Targeted therapies likely result in a slight increase in overall survival (OS) (HR 0.84, 95% CI 0.75, 0.93; moderate certainty) and progression-free survival (PFS) (HR 0.52, 95% CI 0.43, 0.62; moderate certainty). Toxicity had a slightly increased risk (RR 1.19, 95% CI 0.95, 1.48; low certainty). Immunotherapy also showed a likely improvement in PFS (HR 0.60, 95% CI 0.49, 0.73; moderate certainty), while toxicity showed a likely higher risk (RR 2.72, 95% CI 1.24, 5.94; moderate certainty). However, benefits in survival translated to time gains of slightly over a month for OS and less than a month for PFS. No data were reported on performance status (PS), hospital admissions, or quality of life (QoL). Conclusions: Our study suggests some survival benefits with low toxicity from these treatments, but gains are marginal. Uncertainties persist regarding their impact on QoL and outcomes for patients with poor PS. Caution is advised in treatment selection for advanced GC patients, who should actively participate in decision-making. Future research should include diverse patient populations and assess patient-centered outcomes with consistent comparator groups for BSC. Trial Registration: The study protocol was registered in OSF (https://doi.org/10.17605/OSF.IO/7CHX6) on 2022-04-01.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term, an overview of systematic reviews

  • Santero, Marilina|||0000-0001-5371-0979
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Antequera, Alba|||0000-0002-1670-6302
  • Auladell-Rispau, Ariadna|||0000-0002-0364-4827
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Rodríguez-Grijalva, G.
  • Salas-Gama, Karla|||0000-0003-4845-4899
  • Dorantes Romandia, Rosario|||0000-0003-3263-895X
  • Salazar, Josefina|||0000-0002-6448-5946
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Esophageal and gastric cancers are a significant public health problem worldwide, with most patients presenting with advanced-stage disease and, consequently, poor prognosis. Systemic oncological treatments (SOT) have been widely used over more conservative approaches, such as supportive care. Nevertheless, its effectiveness in this scenario is not sufficiently clear. This paper provides an overview of systematic reviews that assessed the effectiveness of SOT compared with the best supportive care (BSC) or placebo in patients with advanced esophageal or gastric cancers in an end-of-life context. We searched MEDLINE, EMBASE, The Cochrane Library, Epistemonikos, and PROSPERO for eligible systematic reviews (SRs) published from 2008 onwards. The primary outcomes were overall survival (OS), progression-free survival (PFS), functional status, and toxicity. Two authors assessed eligibility and extracted data independently. We evaluated the methodological quality of included SRs using the AMSTAR-2 tool and the overlap of primary studies (corrected covered area, CCA). Also, we performed a de novo meta-analysis with data reported for each primary study when it was possible. We assessed the certainty of evidence using the GRADE approach. We identified 16 SRs (19 included trials) for inclusion within this overview. Most reviews had a critically low methodological quality, and there was a very high overlap of primary studies. It is uncertain whether SOT improves OS and PFS over more conservative approaches due to the very low certainty of evidence. The evidence is very uncertain about the effectiveness of SOT for advanced esophageal or gastric cancers. High-quality SRs and further randomized clinical trials that include a thorough assessment of patient-centered outcomes are needed. Open Science Framework, 10.17605/OSF.IO/7CHX6. The online version contains supplementary material available at 10.1186/s12885-021-08330-5.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Systemic oncological treatments in patients with advanced pancreatic cancer: a scoping review and evidence map

  • Salazar, Josefina|||0000-0002-6448-5946
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Meza, Nicolás|||0000-0001-9505-0358
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Rodríguez-Grijalva, Gerardo
  • Santero, Marilina|||0000-0001-5371-0979
  • Selva, Anna|||0000-0002-2754-3158
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Purpose: To identify, describe, and organise currently available evidence regarding systemic oncological treatments (SOTs) (chemotherapy, targeted/biological therapies, and immunotherapy) compared to best supportive care (BSC) for patients with advanced pancreatic cancer (PC). Methods: We conducted a scoping review and evidence mapping, adhering to PRISMA-ScR checklist. We searched MEDLINE, EMBASE, Cochrane Library, Epistemonikos, PROSPERO, and clinicaltrials.gov for eligible studies. We included systematic reviews (SRs), randomised controlled trials (RCTs), quasi-experimental, and observational studies evaluating SOTs compared to BSC or no treatment in patients with advanced PC. Two independent reviewers performed the screening process and data extraction. We developed evidence maps as an interactive visualization display, including the assessed interventions and outcomes. Results: Of the 50,601 records obtained from our search, we included 43 studies: 2 SRs, 16 RCTs, 4 quasi-experimental studies, 20 observational studies, and 1 protocol for a quasi-experimental study. Forty-two studies reported survival-related outcomes and most favoured SOTs, while fve reported toxicity and most favoured BSC. Other patient-centred outcomes, such as quality of life, were scarcely reported. Conclusions: This study highlights the current evidence gaps in studies assessing treatments for patients with advanced PC, mainly the lack of reports of non-survival-related outcomes, pointing out research areas that need further attention to make better recommendations for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers, An Overview of Systematic Reviews

  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Rodríguez-Grijalva, Gerardo
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Santero, Marilina|||0000-0001-5371-0979
  • Salazar, Josefina|||0000-0002-6448-5946
  • Salas-Gama, Karla|||0000-0003-4845-4899
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Antequera, Alba|||0000-0002-1670-6302
  • Auladell-Rispau, Ariadna|||0000-0002-0364-4827
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Hepatobiliary cancers (that include hepatocellular carcinoma, intrahepatic or extrahepatic cholangiocarcinoma and gallbladder cancer) are usually treated with systemic oncological treatments (i.e., chemotherapy, immunotherapy and biological or targeted therapies) mainly due to their improvement in survival. However, the trade-off between these therapies and usual practice supportive care is not clear, and other outcomes beyond survival should be considered in advanced stages, such as quality of life or symptom control. The present study is part of a wider project aiming to conduct broad evidence syntheses assessing the effects of systemic oncological treatments versus usual practice supportive care for patients with advanced non-intestinal digestive cancers. We performed an overview of systematic reviews assessing the effects of systemic oncological treatments versus usual practice supportive care for patients with primary advanced hepatobiliary cancer. We found evidence that for these patients (specifically for advanced hepatocellular carcinoma), systemic oncological treatments tend to improve survival at the expense of greater toxicity. Much of systematic reviews included was of low quality and highly overlapped. Nevertheless, the evidence we found failed to report other important outcomes that could be critical for decision making, including quality of life or symptom control. Future research assessing these patient-important outcomes is needed. Background: The trade-off between systemic oncological treatments (SOTs) and UPSC in patients with primary advanced hepatobiliary cancers (HBCs) is not clear in terms of patient-centred outcomes beyond survival. This overview aims to assess the effectiveness of SOTs (chemotherapy, immunotherapy and targeted/biological therapies) versus UPSC in advanced HBCs. Methods: We searched for systematic reviews (SRs) in PubMed, EMBASE, the Cochrane Library, Epistemonikos and PROSPERO. Two authors assessed eligibility independently and performed data extraction. We estimated the quality of SRs and the overlap of primary studies, performed de novo meta-analyses and assessed the certainty of evidence for each outcome. Results: We included 18 SRs, most of which were of low quality and highly overlapped. For advanced hepatocellular carcinoma, SOTs showed better overall survival (HR = 0.62, 95% CI 0.55-0.77, high certainty for first-line therapy; HR = 0.85, 95% CI 0.79-0.92, moderate certainty for second-line therapy) with higher toxicity (RR = 1.18, 95% CI 0.87-1.60, very low certainty for first-line therapy; RR = 1.58, 95% CI 1.28-1.96, low certainty for second-line therapy). Survival was also better for SOTs in advanced gallbladder cancer. No outcomes beyond survival and toxicity could be meta-analysed. Conclusion: SOTs in advanced HBCs tend to improve survival at the expense of greater toxicity. Future research should inform other patient-important outcomes to guide clinical decision making.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer, A comprehensive scoping review and evidence map

  • Santero, Marilina|||0000-0001-5371-0979
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Selva, Anna|||0000-0002-2754-3158
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Meza, Nicolás|||0000-0001-9505-0358
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Salazar, Josefina|||0000-0002-6448-5946
  • Rodríguez Grijalva, Gerardo
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
To identify, describe, and organize the available evidence regarding systemic oncological treatments compared to best supportive care (BSC) for advanced gastresophageal cancer. We conducted a thorough search across MEDLINE (PubMed), EMbase (Ovid), The Cochrane Library, Epistemonikos, PROSPERO, and Clinicaltrials.gov. Our inclusion criteria encompassed systematic reviews, randomized controlled trials, quasi-experimental and observational studies involving patients with advanced esophageal or gastric cancer receiving chemotherapy, immunotherapy or biological/targeted therapy compared to BSC. The outcomes included survival, quality of life, functional status, toxicity, and quality of end-of-life care. We included and mapped 72 studies, comprising SRs, experimental and observational designs, 12 on esophageal cancer, 51 on gastric cancer, and 10 both locations. Most compared schemes including chemotherapy (47 studies), but did not report therapeutic lines. Moreover, BSC as a control arm was poorly defined, including integral support and placebo. Data favor the use of systemic oncological treatments in survival outcomes and BSC in toxicity. Data for outcomes including quality of life, functional status, and quality of end-of-life care were limited. We found sundry evidence gaps specifically in assessing new treatments such as immunotherapy and important outcomes such as functional status, symptoms control, hospital admissions, and the quality of end-life care for all the treatments. There are important evidence gaps regarding new for patients with advanced gastresophageal cancer and the effect of systemic oncological treatments on important patient-centered outcomes beyond survival. Future research should clearly describe the population included, specifying previous treatments and considering therapeutic, and consider all patient-centered outcomes. Otherwise, it will be complex to apply research results into practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment with anticancer drugs for advanced pancreatic cancer, a systematic review

  • Salazar, Josefina|||0000-0002-6448-5946
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Savall-Esteve, Olga|||0009-0002-2685-1797
  • Antequera, Alba|||0000-0002-1670-6302
  • Bottaro-Parra, David
  • Gutiérrez-Valencia, Marta|||0000-0002-3229-6614
  • Martínez Peralta, Susana|||0000-0002-1117-7667
  • Pericay, Carles|||0000-0002-4975-7851
  • Tibau Martorell, Ariadna|||0000-0003-0229-6987
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Patients with advanced pancreatic cancer have a poor prognosis and high burden of cancer-related symptoms. It is necessary to assess the trade-off of clinical benefits and possible harms of treatments with anticancer drugs (TAD). This systematic review aims to compare the effectiveness of TAD versus supportive care or no treatment, considering all patient-important outcomes. We searched PubMed, Embase, Cochrane Library, and Epistemonikos. Two reviewers performed selection, data extraction and risk of bias assessment. We assessed certainty of the evidence using the GRADE approach. We included 14 randomised controlled trials. Chemotherapy may result in a slight increase in overall survival (MD: 2.97 months (95%CI 1.23, 4.70)) and fewer hospital days (MD: -6.7 (-8.3, -5.1)), however, the evidence is very uncertain about its effect on symptoms, quality of life, functional status, and adverse events. Targeted/biological therapy may result in little to no difference in overall survival and a slight increment in progression-free survival (HR: 0.83 (95%CI 0.63, 1.10)), but probably results in more adverse events (RR: 5.54 (95%CI 1.24, 23.97)). The evidence is very uncertain about the effect of immunotherapy in overall survival and functional status. The evidence is very uncertain about whether the benefits of using treatment with anticancer drugs outweigh their risks for patients with advanced pancreatic cancer. This uncertainty is further highlighted when considering immunotherapy or a second line of chemotherapy and thus, best supportive care would be an appropriate alternative. Future studies should assess their impact on all patient-important outcomes to inform patients in setting their goals of care. The online version contains supplementary material available at 10.1186/s12885-023-11207-4.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

How appropriate is treating patients diagnosed with advanced esophageal cancer with anticancer drugs? A multicenter retrospective cohort Spanish study

  • Santero, Marilina|||0000-0001-5371-0979
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Rodriguez Mesa, Dulce|||0009-0008-7206-2987
  • Bottaro, David
  • Macias Declara, Ismael
  • Pericay, Carles|||0000-0002-4975-7851
  • Farina, Natalie
  • Blanco, Jesus Manuel
  • Urreta-Barallobre, Iratxe|||0000-0003-0498-6033
  • Punti, Laura
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Aim: To assess the appropriateness of systemic oncological treatments (SOT) provided to patients diagnosed with advanced esophageal cancer (EC) across a group of participating hospitals. Methods: Multicenter, retrospective cohort study in five Spanish hospitals including newly confirmed advanced EC cases between July 1, 2014, and June 30, 2016, with a 5-year follow-up. Results: We identified 157 patients fulfilling the inclusion criteria (median age: 65 years, 85.9% males). Most patients, 125 (79.6%) were treated at least with one active treatment, and 33% received two or more lines of SOT. The 1-, 2- and 5-year overall survival rates were 30.3% [95%CI: 23.8, 38.7], 14.0% [95%CI: 9.3, 21.0], and 7.1% [95% CI: 3.8, 13.1] respectively, and the median survival time 8 months (95% CI: 6, 19) for stages IIIb IIIc and 7 months (95% CI: 5, 9) for stage IV. Clinical stage, receiving more than one line of SOT, and treatment with radiotherapy accelerated the time to death (0.4, 0.9-, and 0.8-times shorter survival respectively, p < 0.05). Better performance status (ECOG < 2) extended survival time by 2.2 times (p = 0.04). Age < 65 years (OR 9.4, 95% CI 3.2, 31.4, p < 0.001), and being treated in one particular hospital (OR 0.2, 95% CI 0.0, 0.8, p < 0.01) were associated with the administration of two or more lines of SOT. Altogether, 18.9% and 9.0% of patients received chemotherapy in the last four and two weeks of life, respectively. Moreover, 2.5% of patients were prescribed a new line of chemotherapy during the last month of life. The proportion of all patients who did not have access to palliative care reached 29.3%, and among those who had access to it, 34.2% initiated it in the last month of life. Conclusion: A high proportion of advanced EC patients receive many treatments not based on sound evidence and they do not benefit enough from palliative care services. The most accepted appropriateness indicators point out that some of the analyzed patients could have been overtreated. This study provides important insights into the quality of care provided to advanced EC, and furthermore, for giving valuable insight and opportunities for improvement.